Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation

By  

Molecular and Clinical Oncology, Vol. 3, Iss. 2, 2015-01 ,pp. : 329-333

Science Publishers

Access to resources Recommend Favorite

Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors

By Tsuboi Masahiro   Chevalier Thierry  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 161-170

Humana Press, Inc

Access to resources Recommend Favorite

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

By Riedel Richard F   Febbo Phillip G  

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 461-466

Future Medicine

Access to resources Recommend Favorite

Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer

By Chu Huili   Zhong Chen   Xue Guoliang   Liang Xiuju   Wang Jun   Liu Yingxin   Zhao Shiwei   Zhou Qian   Bi Jingwang  

Oncology Reports, Vol. 30, Iss. 5, 2013-11 ,pp. : 2311-2315

Spandidos Publications

Access to resources Recommend Favorite

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

By Motoshima Kohei   Nakamura Yoichi   Sano Kazumi   Ikegami Yoji   Ikeda Takaya   Mizoguchi Kosuke   Takemoto Shinnosuke   Fukuda Minoru   Nagashima Seiji   Iida Tetsuya   Tsukamoto Kazuhiro   Kohno Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1299-1304

Springer Publishing Company

Access to resources Recommend Favorite